3
results
for author:"Heldens S."
in Literature Citations
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., Ince W.L., Janne P.A., Januario T., Johnson D.H. et al. J. Clin. Oncol. 23:5900-5909(2005) · Mapped (23) |
| The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C. et al. Genome Res. 13:2265-2270(2003) · UniProtKB (1,019) |
| Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Li H., Chen J., Huang A., Stinson J., Heldens S., Foster J., Dowd P., Gurney A.L., Wood W.I. Proc. Natl. Acad. Sci. U.S.A. 97:773-778(2000) · UniProtKB (2) · Mapped (1) |
